College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China; China Institute of Nutritional and Metabolic Disorders in Domestic Animals and Fowls, Nanjing Agricultural University, Nanjing 210095, China; Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing, Jiangsu 210014, China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225009, China.
Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing, Jiangsu 210014, China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225009, China.
Vaccine. 2018 Dec 18;36(52):7929-7935. doi: 10.1016/j.vaccine.2018.11.012. Epub 2018 Nov 20.
The immunological enhancement characteristics of the immunopotentiator CVC1302 were evaluated for foot-and-mouth disease virus (FMDV) inactivated vaccine in pigs. Eight-week-old piglets were vaccinated with the foot-and-mouth disease (FMD) vaccine alone (FMD-vaccine group) or with the addition of CVC1302 (FMD-CVC1302 group), and the serum liquid phase blocking ELISA (LPB-ELISA) antibody titers, IgG1 and IgG2 levels, and the levels of four cytokines secreted by peripheral blood lymphocytes were measured at 28 days post vaccination (dpv). In the FMD-CVC1302 group, the LPB-ELISA antibody titers, IgG1, and IgG2 titers, and IL-2, IL-4, IL-6, and IFN-γ levels at 28 dpv were significantly higher than those in the FMD-vaccine group. The FMD-CVC1302 group had long-lasting antibody titers (>7.8 log), lasting for at least 6 months. In addition, piglets were vaccinated with or without addition of CVC1302 to the FMD vaccine at three different doses (1, 1/3, and 1/9 of the standard vaccine dose) and the serum LPB-ELISA antibody and serum neutralizing (SN) antibody titers were detected at 28 dpv. Then all pigs were challenged with virulent FMDV for PD value, and the levels of FMDV-specific RNA copies for the two full-dose groups at 3 and 10 days post challenge (dpc) were measured. The LPB-ELISA and SN antibody titers for the three doses in the FMD-CVC1302 groups were significantly higher than those in the FMD-vaccine groups at the same doses (p < 0.05). Post-virus challenge, the FMDV-specific RNA copy number in the FMD-CVC1302 group was lower than that in the FMD-vaccine group at 3 and 10 dpc. The PD value was 15.85 for the FMD-CVC1302 group, which was obviously higher than that for the FMD-vaccine group (10.96), and in the 1/9-dose of FMD-vaccine group only 3/5 pigs were protected. These results indicate that CVC1302 can enhance the immune efficacy and protective ability of the FMD vaccine in pigs.
该免疫增强剂 CVC1302 对猪口蹄疫灭活疫苗的免疫增强特性进行了评价。8 周龄仔猪单独接种口蹄疫疫苗（口蹄疫疫苗组）或添加 CVC1302（口蹄疫-CVC1302 组），并在接种后 28 天（dpv）测量血清液相阻断 ELISA（LPB-ELISA）抗体滴度、IgG1 和 IgG2 水平以及外周血淋巴细胞分泌的四种细胞因子水平。在口蹄疫-CVC1302 组中，28 dpv 时的 LPB-ELISA 抗体滴度、IgG1 和 IgG2 滴度以及 IL-2、IL-4、IL-6 和 IFN-γ水平均显著高于口蹄疫疫苗组。口蹄疫-CVC1302 组的抗体滴度持续时间较长（>7.8 log），至少持续 6 个月。此外，猪只分别在接种或不接种 CVC1302 口蹄疫疫苗三种不同剂量（标准疫苗剂量的 1、1/3 和 1/9）下进行免疫，并在 28 dpv 检测血清 LPB-ELISA 抗体和血清中和（SN）抗体滴度。然后所有猪都用强毒口蹄疫病毒攻毒，测量攻毒后 3 天和 10 天（dpc）两组全剂量猪的口蹄疫病毒特异性 RNA 拷贝数。在口蹄疫-CVC1302 组的三个剂量组中，LPB-ELISA 和 SN 抗体滴度均显著高于同剂量的口蹄疫疫苗组（p<0.05）。攻毒后，口蹄疫-CVC1302 组口蹄疫病毒特异性 RNA 拷贝数在 3 和 10 dpc 均低于口蹄疫疫苗组。口蹄疫-CVC1302 组的 PD 值为 15.85，明显高于口蹄疫疫苗组（10.96），而在 1/9 剂量的口蹄疫疫苗组中，只有 3/5 的猪得到保护。这些结果表明，CVC1302 可增强猪对口蹄疫疫苗的免疫效果和保护能力。
